Response to highly active antiretroviral therapy according to duration of HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue 5, 2001, Pages 473-479

  Pezzotti, Patrizio ^a   Pappagallo, Marilena ^a   Phillips, Andrew N ^b   Boros, Stefano ^a   Valdarchi, Catia ^a   Sinicco, Alessandro ^c   Zaccarelli, Mauro ^d   Rezza, Giovanni ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF TURIN   (Italy)

^d Ist Ric Cura Carattere Sci S   (Italy)

Author keywords

Antiretroviral therapy; Cohort study; Effectiveness; HIV seroconverters

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; COHORT ANALYSIS; DISEASE DURATION; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; VIRUS LOAD;

EID: 0035870636     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200104150-00012     Document Type: Article

References (30)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:723-33.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
3. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 1998;280: 35-41.
4. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997;315:1194-9.
5. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352:1725-30.
6. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;38:858-60.
7. Pezzotti P, Napoli PA, Acciai S, et al. Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. AIDS 1999;13:249-55.
8. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997;3:533-40.
9. Gorochov G, Neumann AU, Kereveur A, et al. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat Med 1998;4:215-21.
10. Pantaleo G, Demarest JF, Schacker T, et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997;94:254-8.
11. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261:1179-81.
12. Karlsson AC, Lindback S, Gaines H, et al. Characterization of the viral population during primary HIV-1 infection. AIDS 1998;12: 839-47.
13. Moyle GJ, Gazzard BG, Cooper DA, et al. Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use. Drugs 1998;55:383-404.
14. Mezzaroma I, Carlesimo M, Pinter E, et al. Clinical and immunological response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis 1999;29:1423-30.
15. d'Arminio Monforte A, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998;12:1631-7.
16. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353:863-8.
17. Rezza G, Lazzarin A, Angarano G, et al. The natural history of HIV infection in intravenous drug users: risk of disease progression in a cohort of seroconverters. AIDS 1989;3:87-90.
18. The Italian Seroconversion Study. Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. AIDS 1992;6:421-6.
19. Dorrucci M, Balducci M, Pezzotti P, et al. Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. Italian HIV Seroconversion Study (ISS). J Acquir Immune Defic Syndr 1999;22:65-70.
20. U. S. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(RR-17):1-17.
21. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998;280: 78-86.
22. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283:381-90.
23. BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2000;1:76-101.
24. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995;333: 450-51.
25. Ribeiro R M, Bonhoeffer S. A stochastic model for primary HIV infection: optimal timing of therapy. AIDS 1999;13:351-57.
26. Harrington M, Carpenter CCJ. Hit HIV-1 hard, but only when necessary. Lancet 2000;355:2147-52.
27. Rezza G, Galai N, Pezzotti P, et al. Markers of response to zidovudine monotherapy among treated HIV seroconverters. Antiviral Ther 1997;2:167-74.
28. Junghans C, Low N, Chan P, et al. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 1999;13:2547-54.
29. CASCADE collaboration. Changes in the uptake of antiretroviral therapy and survival in persons with known duration of HIV infection in Europe. HIV Med 2000;1:224-31.
30. Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000;160:1123-32.